CTOs on the Move

Valeant Pharmaceuticals

www.valeant.com

 
Valeant Pharmaceuticals International, Inc. is a diverse and decentralized pharmaceutical company that is committed to focusing on our key stakeholders while delivering consistently high performance. Our values provide the overall direction for our company, and provide us with the tools necessary to rise to any challenge by leveraging our collective hard work and effort along with our unwavering competitive spirit. These values help us set goals based on our organization’s potential and what we hope it will become.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.valeant.com
  • 2150 St. Elzéar Blvd. West
    Laval, QC CAN H7L 4A8
  • Phone: 514.744.6792

Executives

Name Title Contact Details
Michael McDaid
Vice President of Information Technology Profile

Similar Companies

Control and Power Systems Inc

Control and Power Systems Inc is a Fairfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Merck-Medco

Merck-Medco is a Franklin Lakes, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Balt

BALT is a world leader in the design and manufacture of interventional neuroradiology devices to treat neurovascular pathologies (strokes, aneurysms, AVMs).

Oyster Point Pharma

Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.